The Ever-Changing Hard Surface Disinfectant Landscape in COVID-19 times

The Ever-Changing Hard Surface Disinfectant Landscape in COVID-19 times

Published on 14 Apr 2020

Author: Teri Dickinson, Manager, Regulatory Affairs, Dell Tech Laboratories Ltd.

These days, the world of hard surface disinfectants and pathway to registration changes almost weekly.  With the health and safety of Canadians being at the fore front the quick access to disinfectant products has been a top priority. 

Health Canada has implemented interim measures to expedite access to disinfectants to address product shortages and published a list of hard-surface disinfectants that are likely to be effective for use against coronavirus (COVID-19).

Want your product to be on the list?  Want to make indirect efficacy claims for SARS-CoV-2, the virus that causes COVID-19? Your product will need to be reviewed and approved with one or more of the following:

  • labelled as a broad-spectrum virucide, that is supported by an efficacy claim against any of:
    •    Adenovirus type 5
    •    Bovine Parovirus
    •    Canine Parvovirus
    •    Poliovirus type 1
  • carry a specific claim against non-enveloped viruses of the picornaviridae, caliciviridae, astroviridae, reoviridae, or papillomaviridae families or
  • carry a specific claim against a specific coronavirus, such as
    •    MERS-CoV
    •    SARS-CoV
    •    human coronavirus strain 229E

References:

Hard-surface disinfectants and hand sanitizers (COVID-19): List of hard-surface disinfectants 

https://www.canada.ca/en/health-canada/services/drugs-health-products/disinfectants/covid-19/list.html

 

 

Related Articles

Non-medical masks or face coverings: Regulatory considerations in the context of COVID-19

Non-medical masks or face coverings: Regulatory considerations in the context of COVID-19

On July 24, 2020, Health Canada published a notice to industry that explains circumstances under which non-medical masks or face coverings would be subject to the regulatory...

Step 2b draft Q3C(R8): Impurities: Guideline for Residual solvents – Released for public consultation

Step 2b draft Q3C(R8): Impurities: Guideline for Residual solvents – Released for public consultation

The ICH Q3C core guideline was finalized under Step 4 in July 1997, providing recommendations on the use of less toxic solvents in the manufacture of drug substances and...